Cayman Pharma

What Cayman Pharma does

Cayman Pharma s.r.o. is a privately held Czech pharmaceutical manufacturer specializing in cGMP prostaglandin Active Pharmaceutical Ingredients (APIs). Established in October 2006 through the merger of Cayman Chemical Inc. (a US-based research biochemical firm founded in 1980) and NeraPharm (a veterinary prostaglandin producer operating since the late 1970s within the Spolana complex near Prague), the company operates from its headquarters in Neratovice, Czech Republic, approximately 25 km north of Prague. It is a subsidiary of Cayman Chemical Company and employs roughly 130 staff across production, R&D, quality, analytics, and administration.

The company's core technology is a patented synthetic route to the prostaglandin core structure developed over many years of specialized research at its Czech headquarters. Its product portfolio comprises eight distinct cGMP prostaglandin APIs organized into three therapeutic categories: five ophthalmology products (Latanoprostene Bunod, Travoprost, Latanoprost, Bimatoprost, and Tafluprost) used as ocular hypotensive agents for glaucoma; two veterinary products ((+)-Cloprostenol sodium salt and (±)-Cloprostenol sodium salt) used as luteolytic agents for livestock reproduction management; and one vascular product (Epoprostenol sodium salt) for pulmonary hypertension. Manufacturing is verified by regular cGMP audits from Czech regulatory authorities (SÚKL, ÚSKVBL) and the US FDA, with Drug Master Files (DMFs) filed across major pharmaceutical markets including the United States, Canada, Japan, Australia, EU member states, India, and Russia. Products conform to USP, EP, IP, and BVP monographs where applicable.

Cayman Pharma generates revenue through B2B direct sales of pharmaceutical-grade APIs to pharmaceutical manufacturers worldwide. Pricing is quote-based and not publicly disclosed, requiring direct engagement with the API Sales department, consistent with industry practice where contracts are typically multi-year and pricing varies by volume and regulatory jurisdiction. The company maintains ISO 9001, ISO 14001, and ISO 45001 certifications and distributes a secure document portal (Qualitecloud) for technical and regulatory documentation. Its go-to-market is enterprise field sales targeting pharma manufacturers in three segments: ophthalmology/glaucoma drug makers, veterinary pharmaceutical companies, and producers of vascular/cardiovascular therapeutics.

Name

Cayman Pharma

Legal name

Cayman Pharma s.r.o.

Website

https://caymanpharma.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

51–100 employees

Short description

Cayman Pharma is a Czech cGMP manufacturer of prostaglandin Active Pharmaceutical Ingredients serving global pharmaceutical companies in ophthalmology, veterinary, and vascular therapy segments. It operates as a subsidiary of Cayman Chemical Company from its Neratovice facility with roughly 130 employees.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (APIs)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic & Private-Label Veterinary Pharmaceuticals (HLAMAEAM)

akta.pro secondary industry

Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Active pharmaceutical ingredients
• Prostaglandin APIs
• CGMP manufacturing
• Ophthalmic pharmaceuticals
• Veterinary prostaglandins

Headquarters

HQ city

Neratovice

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredient (API) Sales: Sale of cGMP-prostaglandin Active Pharmaceutical Ingredients to pharmaceutical manufacturers for use in finished drug products. Revenue is generated through direct B2B sales of pharmaceutical-grade raw materials used in human and veterinary medicine.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Cayman Pharma manufactures and sells cGMP-grade prostaglandin Active Pharmaceutical Ingredients (APIs) to pharmaceutical manufacturers worldwide. The portfolio spans ophthalmology APIs (Latanoprostene Bunod, Travoprost, Latanoprost, Bimatoprost, Tafluprost) for glaucoma treatment, veterinary APIs ((+)-Cloprostenol sodium salt and (±)-Cloprostenol sodium salt) for livestock reproductive management, and a vascular API (Epoprostenol sodium salt) for pulmonary hypertension. Products are sold as raw pharmaceutical-grade materials under quote-based B2B contracts with regulatory documentation filed in major global markets.

Product overview

Cayman Pharma is a cGMP Prostaglandin Active Pharmaceutical Ingredient (API) manufacturer. The company's product portfolio consists of eight distinct prostaglandin-based APIs organized into three therapeutic categories: five Ophthalmology products (Latanoprostene Bunod, Travoprost, Latanoprost, Bimatoprost, and Tafluprost) used for glaucoma treatment; two Veterinary products ((+)-Cloprostenol sodium salt and (±)-Cloprostenol sodium salt) used as luteolytic agents for reproductive disorders in livestock; and one Vascular product (Epoprostenol sodium salt) used for pulmonary hypertension treatment. Cayman Pharma owns and practices a patented route to the prostaglandin core structure developed at its headquarters near Prague, Czech Republic. GMP compliance is verified by Czech regulatory authorities (SÚKL, ÚSKVBL) and US FDA. Products are sold as APIs to pharmaceutical manufacturers worldwide with DMFs filed in major markets including the US, Canada, EU, Japan, Australia, India, and Russia.

Differentiator

Problem solved

Functional benefit

Products and services

• Latanoprostene Bunod A nitric oxide-donating FP receptor agonist cGMP API used for the treatment of elevated intraocular pressure (IOP) in glaucoma. GMP material is available and DMF is available for customer review upon request. Sold to pharmaceutical manufacturers of ophthalmic drugs.
• Travoprost A potent FP receptor agonist cGMP API used as an ocular hypotensive agent for the treatment of glaucoma. Conforms to USP Monograph. DMF on file with US FDA, Canada, India, Japan, China, and several EU member states. Sold to ophthalmic pharmaceutical manufacturers.
• Latanoprost The most widely used prostaglandin for treatment of elevated IOP in glaucoma. GMP material conforming to USP, EP, and IP Monographs is available. Manufactured at both Cayman Chemical (Ann Arbor, MI) and Cayman Pharma (Czech subsidiary). Sold to ophthalmic pharmaceutical manufacturers.
• Bimatoprost A potent FP receptor agonist cGMP API used as an ocular hypotensive agent for the treatment of glaucoma. DMF is on file with US FDA, Canada, and India. Sold to ophthalmic pharmaceutical manufacturers.
• Tafluprost A potent FP receptor agonist cGMP API for the treatment of elevated intraocular pressure (IOP) in glaucoma. DMF has been filed with US FDA and Russia. Sold to ophthalmic pharmaceutical manufacturers.
• (+)-Cloprostenol sodium salt The active enantiomer of Cloprostenol, a cGMP veterinary API used as a luteolytic agent for induction of estrus and treatment of reproductive disorders in cattle, swine, and horses. ASMF is on file in UK, Switzerland, and most EU countries. Sold to veterinary pharmaceutical manufacturers.
• (±)-Cloprostenol sodium salt A cGMP veterinary API used as a luteolytic agent for induction of estrus and treatment of reproductive disorders in cattle, swine, and horses. Conforms to USP and BVP Monographs. DMF is on file with US FDA, Canada, Russia, and almost all EU member states. Sold to veterinary pharmaceutical manufacturers.
• Epoprostenol sodium salt A potent vasodilator and antiplatelet cGMP API with a very short physiologic half-life, used for the treatment of pulmonary hypertension. DMF on file with US FDA, Canada, Japan, Australia, and many EU member states. Sold to vascular/cardiovascular pharmaceutical manufacturers.

Quantifiable outcome

• Products conform to USP, EP, IP, and BVP Monographs
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Cayman Chemical Inc.coreStrategic or Co-development Partner · 1 October 2006Parent company established in 1980, Cayman Chemical Inc. is a globally recognized research biochemical company and expert in lipid chemistry. Following acquisition of NeraPharm, Cayman Chemical established Cayman Pharma s.r.o. to focus on prostaglandins used in human medicine. Cayman Chemical brings cutting-edge knowledge in research of advanced prostaglandin compounds to the partnership.

Scale indicators4 records

Recent moves1 record

Expansion highlights4 records

Direct peers

• Cayman Chemical Inc. Cayman Pharma's parent company and direct sibling in the Cayman group; both specialize in prostaglandin chemistry and APIs/research biochemicals, with shared scientific talent pool and overlapping product portfolio.
• LKT Laboratories: Smaller specialty research biochemicals and small-molecule API manufacturer with overlapping lipid/prostaglandin chemistry focus and similar target customers in pharma research and development.

Broad incumbents

• Hovione: Specialty API and contract manufacturer with strong prostaglandin and steroid expertise, FDA-inspected sites, and global regulatory filings — directly comparable customer segments and quality systems.
• Olon S.p.A. Large generic API manufacturer with a focus on steroids and prostaglandin chemistry (latanoprost, bimatoprost), operating from Italy/Europe with FDA-inspected facilities and multi-jurisdictional DMF filings.
• MilliporeSigma (Sigma-Aldrich): Major global supplier of research biochemicals, fine chemicals, and select cGMP APIs; relevant peer given Cayman Chemical's dual identity as a research-biochemical supplier and Cayman Pharma's API focus on the same chemistry.
• Cambrex: Global small-molecule API and contract manufacturer serving branded and generic pharma with comparable cGMP capabilities, regulatory filing infrastructure, and B2B API supply model.
• Johnson Matthey (Pharma Solutions): Global fine chemicals and API manufacturer offering API supply, regulatory support, and CDMO services to pharma customers — comparable in product breadth, scale, and B2B API commercial model.
• Bachem: Specialty API manufacturer (peptides and small molecules) with comparable cGMP infrastructure, regulatory filings, and B2B pharma supply model targeting ophthalmology, endocrinology, and rare-disease indications.
• Teva Active Pharmaceutical Ingredients: One of the world's largest generic API manufacturers offering a broad steroid, prostaglandin, and small-molecule API portfolio with comparable cGMP manufacturing scale and global DMF footprint.
• ScinoPharm Taiwan: Taiwan-based API manufacturer with global DMF filings serving generic pharmaceutical customers; a comparable Asian-sourced API alternative for buyers diversifying away from EU sole-source suppliers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/CaymanPharma
• LinkedInlinkedin.com/company/cayman-pharma-s-r-o-

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cayman Pharma